Arcutis Q1 Revenue Surges 65% but Sequential Dip Raises Seasonality Questions

What happened

Arcutis Biotherapeutics reported Q1 2026 net revenues of $105.4 million, up 65% year-over-year, but down 17% sequentially due to typical first-quarter deductible resets and insurance changes. The company reaffirmed full-year 2026 revenue guidance of $480–495 million and achieved positive operating cash flow of $2.2 million, a significant improvement from a year ago. Management highlighted ZORYVE's expanding indications and prescriber base, including a ~48% branded non-steroidal topical share and ~21,000 weekly prescriptions. Near-term focus is on a sequential revenue re-acceleration in Q2 and the June 29 FDA action date for pediatric psoriasis down to age 2. Investors should scrutinize whether the deductible reset headwind is temporary and if operating leverage can sustain as SG&A continues to rise.

Implication

The near-term investment case hinges on two concrete proof points: Q2 2026 net product revenue must rebound sequentially from Q1's $105.4 million to validate that the deductible reset was a one-time headwind, and the FDA must approve ZORYVE for pediatric psoriasis by June 29 to expand the addressable market. If Q2 revenue fails to accelerate and operating cash flow turns negative, the thesis of a scaled, self-funding franchise weakens. Conversely, positive FDA news and strong Q2 results could propel the stock toward our base case of $24. Investors should size positions accordingly between $19 and $28, with a re-assessment window after Q2 results. The debt covenant (75% of internal revenue projections) adds downside risk if demand stalls.

Thesis delta

The narrative shifts from a pure growth story to one where quarterly volatility and operating leverage are key. The market now focuses on Q2's sequential revenue rebound and the upcoming FDA decision as proof points, rather than just top-line growth. The earlier assumption of smooth growth is replaced by a need to demonstrate that seasonality is a temporary headwind, not a demand deterioration.